Igor Maslovsky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Igor Maslovsky has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
D. Gefel
Department of Internal Medicine
2 shared publicationsDov Gefel
Barzilai Medical Center, Ashkelon, Israel
2 shared publicationsG. Lugassy
Department of Hematology, Barzilai Medical Center, Ashkelon, Israel
2 shared publicationsD. Ben Dor
Institute of Pathology, Barzilai Medical Center, Ashkelon, Israel
1 shared publicationDavid Ben-Dor
1 shared publicationFrida Barak
1 shared publication
Latest Publications
- Open Access
- 1 January 2013
- Published by Herbert Publications PVT LTD in Pathology Discovery
- Vol. 2 (1) , 2
Adrenal lipoadenoma
Presence of mature adipose tissue, lymphoid infiltration, and bone marrow cells is a rare but well-known occurrence in the adrenal cortex and in both hyperplastic and neoplastic adrenocortical lesions. We present a case and
- 1 January 2013
- Published by Herbert Publications PVT LTD in Pathology Discovery
- Vol. 2 (1) , 2
Open AccessAdrenal lipoadenoma
Presence of mature adipose tissue, lymphoid infiltration, and bone marrow cells is a rare but well-known occurrence in the adrenal cortex and in both hyperplastic and neoplastic adrenocortical lesions. We present a case and
- 1 May 2007
- Published by Wolters Kluwer Health in Journal of Wound, Ostomy & Continence Nursing
- Vol. 34 (3) , 297-298
Extravasation Injury as a Result of VAD Chemotherapy
- 1 May 2007
- Published by Wolters Kluwer Health in Journal of Wound, Ostomy & Continence Nursing
- Vol. 34 (3) , 297-298
Extravasation Injury as a Result of VAD Chemotherapy
- 1 April 2006
- Published by Elsevier in The American Journal of Medicine
- Vol. 119 (4) , 368
Paget-von Schrötter Syndrome
- 1 April 2006
- Published by Elsevier in The American Journal of Medicine
- Vol. 119 (4) , 368
Paget-von Schrötter Syndrome
- 1 February 2006
- Published by Elsevier in The American Journal of Medicine
- Vol. 119 (2) , 180-181
Virchow’s Node and Horner’s Syndrome
- 1 February 2006
- Published by Elsevier in The American Journal of Medicine
- Vol. 119 (2) , 180-181
Virchow’s Node and Horner’s Syndrome
- 1 January 2006
- Published by Wiley
- Vol. 85 (7) , 887-888
Polycythemia as a result of ectopic erythropoietin production in benign cystic leiomyoma of uterus
- 1 January 2006
- Published by Wiley
- Vol. 85 (7) , 887-888
Polycythemia as a result of ectopic erythropoietin production in benign cystic leiomyoma of uterus
- 30 November 2005
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 16 (7) , 523-524
Malignant thymoma complicated by amegakaryocytic thrombocytopenic purpura
- 30 November 2005
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 16 (7) , 523-524
Malignant thymoma complicated by amegakaryocytic thrombocytopenic purpura
- Open Access
- 28 March 2005
- Published by Wiley in American Journal of Hematology
- Vol. 78 (4) , 261-264
Intravenous iron in a primary‐care clinic
The preferable route of iron delivery for most iron‐deficient patients is oral. Parenteral iron therapy is used in patients who cannot tolerate oral iron or in cases in which oral iron is not sufficiently effective. The most frequent indications for parenteral iron therapy are unbearable gastrointestinal side effects induced by oral iron itself, worsening of inflammatory bowel disease symptoms, insufficient intestinal absorption, renal failure‐caused anemia that is treated with erythropoietin, and unresolved ongoing bleeding, which would cause the acceptable oral doses of iron therapy to be exceeded. The serious adverse effects of iron dextran that was used in the past could explain the reluctance of medical personnel to prescribe this effective treatment. Patients with iron deficiency anemia were treated with intravenous iron in a primary care clinic. The iron gluconate was given in a dosage of 62.5 mg diluted in 150 mL of normal saline and was infused intravenously over 30 min, while iron sucrose was given in a dosage of 100 mg diluted in the same volume of normal saline and given at the same rate. In total, 724 infusions were administered to 57 patients. Iron sucrose was used in 628 infusions, and iron gluconate was used in the remaining 96. The frequency of the infusion treatments depended on the underlying disease and ranged from three times a week to once a month. Adverse effects were seldom observed and were minor in patients receiving iron gluconate, and were not registered at all in patients treated with iron sucrose. Two cases of flushing with paresthesias occurred. Slowing the infusion rate successfully eliminated these side effects. One case of hypotension was treated successfully with 500 cc of normal saline infusion. One case of dropout occurred, due to the patient's refusal to cooperate. No anaphylactic reactions were observed. Iron gluconate and iron sucrose are effective and safe for use in primary care clinics. The risk of adverse effects is low. Am. J. Hematol. 78:261–264, 2005.
- 28 March 2005
- Published by Wiley in American Journal of Hematology
- Vol. 78 (4) , 261-264
Open AccessIntravenous iron in a primary‐care clinic
The preferable route of iron delivery for most iron‐deficient patients is oral. Parenteral iron therapy is used in patients who cannot tolerate oral iron or in cases in which oral iron is not sufficiently effective. The most frequent indications for parenteral iron therapy are unbearable gastrointestinal side effects induced by oral iron itself, worsening of inflammatory bowel disease symptoms, insufficient intestinal absorption, renal failure‐caused anemia that is treated with erythropoietin, and unresolved ongoing bleeding, which would cause the acceptable oral doses of iron therapy to be exceeded. The serious adverse effects of iron dextran that was used in the past could explain the reluctance of medical personnel to prescribe this effective treatment. Patients with iron deficiency anemia were treated with intravenous iron in a primary care clinic. The iron gluconate was given in a dosage of 62.5 mg diluted in 150 mL of normal saline and was infused intravenously over 30 min, while iron sucrose was given in a dosage of 100 mg diluted in the same volume of normal saline and given at the same rate. In total, 724 infusions were administered to 57 patients. Iron sucrose was used in 628 infusions, and iron gluconate was used in the remaining 96. The frequency of the infusion treatments depended on the underlying disease and ranged from three times a week to once a month. Adverse effects were seldom observed and were minor in patients receiving iron gluconate, and were not registered at all in patients treated with iron sucrose. Two cases of flushing with paresthesias occurred. Slowing the infusion rate successfully eliminated these side effects. One case of hypotension was treated successfully with 500 cc of normal saline infusion. One case of dropout occurred, due to the patient's refusal to cooperate. No anaphylactic reactions were observed. Iron gluconate and iron sucrose are effective and safe for use in primary care clinics. The risk of adverse effects is low. Am. J. Hematol. 78:261–264, 2005.